Aeolus Pharmaceuticals Announces Fiscal Year 2012 Results
02 janv. 2013 10h59 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jan 2, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus' AEOL 10150 Supresses Overexpression of 31 Hypoxia-Related Genes Caused by Radiation Exposure
17 oct. 2012 08h55 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 17, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
AEOL 10150 improves tissue oxygenation and reduces hypoxia-associated...
Aeolus Pharmaceuticals Provides Positive Update on FDA Meeting
06 sept. 2012 08h05 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Sep 6, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2012 Financial Results
14 août 2012 17h02 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Aug 14, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS)
$1.4 million in revenue for third quarter 2012; $5.9...
Aeolus Pharmaceuticals Announces AEOL 10150 Diminishes Oxidative Stress and Nerve Damage Following Exposure to Nerve Agent
30 juil. 2012 08h48 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jul 30, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces AEOL 10150 Reduces Lung Damage After Neupogen(R) Treatment Following Radiation Exposure
01 juin 2012 08h58 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jun 1, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2012 Financial Results
14 mai 2012 19h48 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - May 14, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS)
$2.2 million in revenue for second quarter 2012; $4.4...
PositiveID Corporation Collaborates With the University of Nevada to Complete Development of Its Biodosimetry Cartridge for Measuring Radiation
14 mai 2012 08h30 HE
|
PositiveID Corporation
DELRAY BEACH, Fla., May 14, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes...
BARDA Exercises $9.1 Million in Contract Options With Aeolus
16 avr. 2012 08h41 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 16, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (OTCBB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of...
BARDA Delivers Notice of Intent to Exercise Additional Contract Options With Aeolus Worth $9.1 Million
09 avr. 2012 04h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Apr 9, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
BARDA notice of intent to exercise options valued at...